Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Apr 29, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection," is looking at whether a nutritional supplement called coenzyme Q10 can help people who have experienced health issues after the train derailment in East Palestine, Ohio, in February 2023. The study aims to see if this supplement can reduce symptoms, improve quality of life, and enhance physical function for those affected. It’s important to note that this is an early-stage study, meaning it will help gather information for a larger future study but is not designed to prove the supplement's effectiveness right away.

To participate, individuals must have lived within 10 miles of the derailment site and have experienced ongoing symptoms—like fatigue, pain, or mood changes—that have lasted for more than six months and may have worsened since the incident. Participants should be tech-savvy enough to complete surveys online and be willing to take part in study activities. If someone is currently involved in another clinical trial or has certain health conditions that could complicate the results, they may not be eligible. The study is not yet open for recruitment, but it represents an opportunity for residents affected by the derailment to contribute to research that may lead to better health outcomes in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • On Feb. 3, 2023, lived within 10 miles of the East Palestine, OH train derailment (closer in will receive preference). Others who were in the area for toxin mitigation and other reasons and show compatible symptoms will also be eligible.
• • Meets Kansas symptom criteria for multi-symptom illness - originally defined for Gulf War Illness (has persistent symptoms, lasting greater than six months, that are of \>mild severity in at least three of the six domains of fatigue/sleep, pain, neurological/cognitive/mood, gastrointestinal, respiratory and dermatologic). At least some symptoms must be new or worsened since the derailment.
• • Access to internet and smart phone or computer for remote Qualtrics survey participation.
• • Willing to perform the stipulated study elements.
• • Took ≥80% of run-in soft gels.
• Exclusion Criteria:
• • Anticipated move from the area or other anticipated obstacle to participating for study duration.
• • Participating in another clinical trial.
• • Has a pre-existing health condition expected to produce significant and variable fluctuating symptoms (e.g. chronic infection and/or active cancer other than non-melanoma skin cancer).
• • Contraindications to CoQ10, such as use of coumadin (although an interaction with CoQ10 is controversial).